Amarantus BioScience (AMBS) 10-Q 7 Nov 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 07, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'Amarantus Bioscience Holdings, Inc.	'
Entity Central Index Key	'0001424812	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'AMBS	'
Entity Common Stock, Shares Outstanding	'	799,653,708
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$680	$1,033
Restricted cash	129	0
Deferred funding fees, net	0	109
Prepaid expenses and other current assets	292	106
Total current assets	1,101	1,248
Property and equipment, net	127	0
Intangible assets, net	1,529	611
Total assets	2,757	1,859
Current liabilities:	'	'
Accounts payable (includes related parties $414 and $490, respectively)	2,276	972
Related party liabilities and accrued interest	251	248
Accrued expenses	302	292
Accrued interest	60	112
Demand promissory note	500	0
8% Senior convertible debentures, net of discount	0	932
Convertible promissory notes	0	124
Derivative liability	0	5,859
Total current liabilities	3,389	8,539
Total liabilities	3,389	8,539
Commitments and contingencies	'	'
Series D convertible preferred stock, $1,000 stated value; 1,300 shares designated; 1,299.327 issued and outstanding as of December 31, 2013	0	839
Stockholders' equity (deficit)	'	'
Common stock, $0.001 par value - 2,000,000,000 and 1,000,000 shares authorized as of September 30,2014 and December 31, 2013, respectively; 786,924,849 and 574,171,945 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	787	574
Additional paid-in capital	38,816	18,938
Accumulated deficit	-41,075	-27,032
Total stockholders' equity (deficit)	-632	-7,519
Total liabilities and stockholders' equity (deficit)	2,757	1,859
Series A Convertible Preferred Stock [Member]	'	'
Stockholders' equity (deficit)	'	'
Preferred Stock, Value, Issued	0	0
Series B Convertible Preferred Stock [Member]	'	'
Stockholders' equity (deficit)	'	'
Preferred Stock, Value, Issued	0	0
Series C Convertible Preferred Stock [Member]	'	'
Stockholders' equity (deficit)	'	'
Preferred Stock, Value, Issued	1	1
Series D Convertible Preferred Stock [Member]	'	'
Stockholders' equity (deficit)	'	'
Preferred Stock, Value, Issued	$839	$0

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Accounts Payable, Related Parties, Current	$414	$490
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Common Stock, Par or Stated Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	2,000,000,000	1,000,000
Common Stock, Shares Issued	786,924,849	574,171,945
Common Stock, Shares Outstanding	786,924,849	574,171,945
Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Series A Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00
Preferred Stock Shares, Designated	250,000	250,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series B Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00
Preferred Stock Shares, Designated	3,000,000	3,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series C Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00
Preferred Stock Shares, Designated	750,000	750,000
Preferred Stock, Shares Issued	750,000	750,000
Preferred Stock, Shares Outstanding	750,000	750,000
Series D Convertible Preferred Stock [Member]	'	'
Temporary Equity, Stated Value	'	$1,000
Temporary Equity, Shares Designated	'	1,300
Temporary Equity, Shares Issued	'	1,299
Temporary Equity, Shares Outstanding	'	1,299
Preferred Stock, Par or Stated Value Per Share	$1,000	'
Preferred Stock Shares, Designated	1,300	'
Preferred Stock, Shares Issued	1,299	'
Preferred Stock, Shares Outstanding	1,299	'

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net sales	$0	$0	$0	$0
Operating expense:	'	'	'	'
Research and development	1,899	289	4,056	1,427
General and administrative	2,070	390	5,289	2,441
Total operating expenses	3,969	679	9,345	3,868
Loss from operations	-3,969	-679	-9,345	-3,868
Other income (expense):	'	'	'	'
Interest expense	-46	-517	-756	-1,658
Loss on issuance of common stock	-193	0	-260	0
Loss on issuance of warrants	0	0	-3,868	0
Other Income (Expense)	-74	0	-92	0
Change in fair value of warrant & derivative liabilities	-117	-1,844	356	-3,349
Total other income (expense)	-430	-2,361	-4,620	-5,007
Net loss	-4,399	-3,040	-13,965	-8,875
Preferred stock dividend	26	12	78	12
Net loss attributable to common stockholders	($4,425)	($3,052)	($14,043)	($8,887)
Basic and diluted net (loss) per common share (in dollars per share)	($0.01)	($0.01)	($0.02)	($0.02)
Basic and diluted weighted average common shares outstanding (in shares)	767,657,531	478,883,561	711,302,222	415,163,655

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
In Thousands, except Share data
Balances at Dec. 31, 2013	($7,519)	$1	$574	$18,938	($27,032)
Balances (in shares) at Dec. 31, 2013	'	750,000	574,171,945	'	'
Common stock issued for services	184	0	2	182	0
Common stock issued for services (in shares)	'	0	2,500,000	'	'
Common stock issued for license	228	0	4	224	0
Common stock issued for license (in shares)	'	0	3,641,002	'	'
Common stock sold	400	0	4	396	0
Common stock sold (in shares)	'	0	4,000,000	'	'
Common stock issued in settlement of convertible promissory notes	11	0	1	10	0
Common stock issued in settlement of convertible promissory notes (in shares)	'	0	1,095,759	'	'
Deferred funding costs charged to equity upon sale of common stock	-400	0	0	-400	0
Common stock issued for funding fees	516	0	6	510	0
Common stock issued for funding fees (in shares)	'	0	6,000,000	'	'
Common stock issued upon conversion of 8% senior convertible debentures	3,091	0	78	3,013	0
Common stock issued upon conversion of 8% senior convertible debentures (in shares)	'	0	77,405,866	'	'
Common stock issued for Series D convertible preferred stock dividend	26	0	1	25	0
Common stock issued for Series D convertible preferred stock dividend (in shares)	'	0	866,218	'	'
Loss on issuance of common stock	67	0	0	67	0
Common stock issued upon exercise of common stock warrants	3,600	0	60	3,540	0
Common stock issued upon exercise of common stock warrants (in shares)	'	0	60,000,000	'	'
Deferred funding costs charged to equity upon exercise of warrants	-190	0	0	-190	0
Loss on issuance of warrants	3,867	0	0	3,867	0
8% senior convertible debentures and convertible notes converted and associated reclassification of derivative liability	3,044	'	0	3,044	0
Series D convertible preferred stock 8% dividend accrued at period end	-26	'	0	0	-26
Stock-based compensation expense	202	0	0	202	0
Net loss	-5,542	0	0	0	-5,542
Balances at Mar. 31, 2014	1,559	1	730	33,428	-32,600
Balances (in shares) at Mar. 31, 2014	'	750,000	729,680,790	'	'
Common stock issued for services	410	0	4	406	0
Common stock issued for services (in shares)	'	0	4,229,818	'	'
Common stock issued for license	126	0	2	124	0
Common stock issued for license (in shares)	'	0	1,858,998	'	'
Common stock issued in settlement of convertible promissory notes	21	0	1	20	0
Common stock issued in settlement of convertible promissory notes (in shares)	'	0	1,062,667	'	'
Common stock sold - LPC	146	0	2	144	0
Common stock sold - LPC (in shares)	'	0	1,500,000	'	'
Deferred funding costs charged to equity upon sale of common stock - LPC	-118	0	0	-118	0
Common stock issued as consideration for commitment fee - LPC	2	0	0	2	0
Common stock issued as consideration for commitment fee - LPC (in shares)	'	0	25,463	'	'
Common stock issued upon conversion of 8% senior convertible debentures	182	0	4	178	0
Common stock issued upon conversion of 8% senior convertible debentures (in shares)	'	0	4,567,534	'	'
Common stock issued for Series D convertible preferred stock dividend	26	0	1	25	0
Common stock issued for Series D convertible preferred stock dividend (in shares)	'	0	866,218	'	'
Common stock issued upon exercise of common stock warrants	167	0	3	164	0
Common stock issued upon exercise of common stock warrants (in shares)	'	0	2,777,775	'	'
8% senior convertible debentures and convertible notes converted and associated reclassification of derivative liability	230	'	0	230	0
Reclassification of series D convertible preferred stock into stockholders' equity (deficit)	839	839	0	0	0
Reclassification of series D convertible preferred stock into stockholders' equity (deficit) (in shares)	'	1,299	0	'	'
Series D convertible preferred stock 8% dividend accrued at period end	-26	'	0	0	-26
Stock-based compensation expense	274	0	0	274	0
Net loss	-4,025	0	0	0	-4,025
Balances at Jun. 30, 2014	-187	840	747	34,877	-36,651
Balances (in shares) at Jun. 30, 2014	'	751,299	746,569,263	'	'
Common stock issued for services	54	0	1	53	0
Common stock issued for services (in shares)	'	0	737,277	'	'
Common stock issued in settlement of convertible promissory notes	107	0	5	102	0
Common stock issued in settlement of convertible promissory notes (in shares)	'	0	4,880,487	'	'
Common stock sold - LPC	1,330	0	9	1,321	0
Common stock sold - LPC (in shares)	'	0	9,000,000	'	'
Deferred funding costs charged to equity upon sale of common stock	35	'	'	'	'
Common stock issued as consideration for commitment fee - LPC	35	0	0	35	0
Common stock issued as consideration for commitment fee - LPC (in shares)	'	0	232,785	'	'
Common stock issued upon conversion of 8% senior convertible debentures	180	0	4	176	0
Common stock issued upon conversion of 8% senior convertible debentures (in shares)	'	0	4,500,009	'	'
Common stock issued for Series D convertible preferred stock dividend	26	0	1	25	0
Common stock issued for Series D convertible preferred stock dividend (in shares)	'	0	866,218	'	'
Loss on issuance of common stock	193	0	0	193	0
Common stock issued upon exercise of common stock warrants	1,208	0	20	1,188	0
Common stock issued upon exercise of common stock warrants (in shares)	'	0	20,138,810	'	'
8% senior convertible debentures and convertible notes converted and associated reclassification of derivative liability	407	'	0	407	0
Series D convertible preferred stock 8% dividend accrued at period end	-26	'	0	0	-26
Stock-based compensation expense	439	0	0	439	0
Net loss	-4,399	0	0	0	-4,399
Balances at Sep. 30, 2014	($632)	$840	$787	$38,816	($41,075)
Balances (in shares) at Sep. 30, 2014	'	751,299	786,924,849	'	'

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)	3 Months Ended			9 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2014	Sep. 30, 2013
Preferred Stock, Dividend Rate, Percentage	8.00%	8.00%	8.00%	'	'
Series D Convertible Preferred Stock [Member]	'	'	'	'	'
Preferred Stock, Dividend Rate, Percentage	8.00%	8.00%	8.00%	8.00%	8.00%

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities	'	'
Net loss	($13,965)	($8,875)
Adjustments to reconcile net loss to net cash used in operating activities	'	'
Depreciation and amortization	17	0
Amortization of debt discount	582	937
Amortization of deferred financing fees	145	194
Amortization of intangibles	86	0
Stock issued for services	648	65
Write-off of clinical trial material	500	0
Reserve for investment	25	0
Loss on stock issuance	260	0
Loss on warrant issuance	3,868	0
Non-cash interest expense related to demand promissory note, warrants and derivatives	37	0
Change in fair value of warrants and derivative liability	-356	3,348
Stock-based compensation expense	914	682
Changes in assets and liabilities:	'	'
Restricted cash	-129	0
Clinical trial material	-500	0
Deferred funding fees	116	0
Prepaid expenses and other current assets	-180	-162
Accounts payable	947	739
Related party liabilities and accrued interest	3	25
Accrued expenses and accrued interest	57	420
Net cash used in operating activities	-6,926	-2,627
Cash flows from investing activities	'	'
Acquisition of property and equipment	-144	0
Investment	-25	0
Acquisition of other assets	-600	-34
Net cash used by investing activities	-769	-34
Cash flows from financing activities	'	'
Proceeds from demand and convertible notes	500	3,823
Repayment of convertible promissory notes and accrued interest	-9	-301
Repayment of convertible promissory notes	0	-3
Proceeds from issuance of common stock	1,876	0
Proceeds from exercise of warrants	4,975	0
Net cash provided by financing activities	7,342	3,519
Net (decrease) increase in cash and cash equivalents	-353	858
Cash and cash equivalents Beginning of period	1,033	157
Cash and cash equivalents End of period	680	1,105
Supplemental schedule of non-cash activities:	'	'
Convertible debentures converted and associated reclassification of derivative liabilities	8,957	0
Debt discount associated with convertible promissory notes	-1,823	0
Convertible promissory notes issued for payables and accrued liabilities	-2	161
Convertible notes payable issued for accounts payables	0	201
Stock issued for deferred funding fees	523	0
Stock subscription	146	0
Intangible asset	-50	0
Deferred funding fees charged to equity upon sale of common stock	-518	0
Stock issued to acquire intangible assets	104	79
Reclass of Series D Preferred from mezzanine to equity	839	0
Stock issued to satisfy accounts payable and accrued expenses	22	1,295
Stock issued for convertible promissory notes	11	1,198
Stock issued for notes payable	0	1,350
Stock issued for warrant obligations	0	78
Debt discount for derivative conversion feature	0	2,178
Series D convertible preferred stock 8% dividend accrued at period end	0	-12
Supplemental cash flow information	'	'
Interest payments	$1	$0

CONDENSED_CONSOLIDATED_STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	3 Months Ended			9 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2014	Sep. 30, 2013
Preferred Stock, Dividend Rate, Percentage	8.00%	8.00%	8.00%	'	'
Series D Convertible Preferred Stock [Member]	'	'	'	'	'
Preferred Stock, Dividend Rate, Percentage	8.00%	8.00%	8.00%	8.00%	8.00%

GENERAL

GENERAL	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature Of Operations [Text Block]	'
	1	GENERAL
	Amarantus Bioscience Holdings, Inc. (the “Company”), is a biotechnology company focused on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and ophthalmological disorders. Through September 30, 2014, the Company has been primarily engaged in biotechnology and diagnostics research and development and raising capital to fund its operations.
	Basis of Presentation
	The accompanying unaudited condensed financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of June 30, 2014, condensed consolidated statements of audited interim financials include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
	The results for the statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2014 or for any future interim period. The condensed balance sheet at December 31, 2013 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2013, and notes thereto included in the Company’s annual report on Form 10-K.
	Significant Accounting Policies
	There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 22, 2014. .
	As the Company has not yet commenced any revenue-generating operations, does not have cash flows from operations, and is dependent on debt and equity funding to finance its operations, the Company is considered a development stage company, as defined by FASB. The Company’s activities are subject to significant risks and uncertainties, as described in the liquidity and going concern footnote, including failing to secure additional funding to operationalize the Company’s current projects and technology before another company develops similar therapeutic platform technologies.
	In June 2014, as discussed below the Financial Accounting Standards Board issued new guidance that removed all incremental financial reporting requirements from U.S. GAAP for development stage entities. The Company early adopted this new guidance effective June 30, 2014, as a result of which all inception-to-date financial information and disclosures have been omitted from this report.
	Recently Issued Accounting Pronouncements
	Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation removes all incremental financial reporting requirements for development stage entities, including the removal of reporting of the cumulative results of operations and cash flows for the period from inception to the end of the current period.  The update is effective for the first annual period beginning after December 15, 2014. Early adoption is permitted, and the Company has decided to adopt this change effective with its form 10-Q filing for the period ending June 30, 2014.
	Accounting Standard Update No. 2014-12, Compensation – stock requires that a performance target that affects vesting and that could be achieved after the requisite service period should be treated as a performance condition that affects vesting, rather than a condition that affects the grant-date fair value. The effective date will be for fiscal years, and interim periods within those years, beginning after December 15, 2015 for all entities. Early adoption is permitted. The Company is considering the effect of this FASB issuance, on the financial statements, and has decided not to early adopt at this time.
	Accounting Standard Update No. ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments in this update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.

LIQUIDITY_AND_GOING_CONCERN

LIQUIDITY AND GOING CONCERN	9 Months Ended
	Sep. 30, 2014
Liquidity And Going Concern [Abstract]	'
Liquidity And Going Concern [Text Block]	'
	2	LIQUIDITY AND GOING CONCERN
	The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings.
	The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.
	As of September 30, 2014, the Company had cash and cash equivalents of approximately $680. Historically, the Company has net losses and negative cash flows from operations. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

RESTATEMENT_OF_PRIOR_QUARTERS

RESTATEMENT OF PRIOR QUARTERS	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]	'
Accounting Changes and Error Corrections [Text Block]	'
		3	RESTATEMENT OF PRIOR QUARTERS
	In the fourth quarter of 2013, we discovered that some of the amounts we had previously reported in prior quarters had not been recorded correctly. The adjustments to correct for accounting differences were made in the fourth quarter of 2013 and are primarily related to our accounting for convertible note obligations.
	The following table sets forth the effects of the restatement on affected items within our previously reported Condensed Consolidated Statement of Operations for the three and nine months ended September 30, 2013.
			Three Months Ended						Nine Months Ended
			September 30, 2013						September 30, 2013
			As Reported			As Restated			As Reported			As Restated
	Operating loss		$	(679	)	$	(679	)	$	(3,868	)	$	(3,868	)
	Non-operating income (loss)			(1,347	)		(2,361	)		(1,916	)		(5,007	)
	Net loss			(2,026	)		(3,040	)		(5,784	)		(8,875	)
	Net loss per common share, basic and diluted			(0.00	)		(0.01	)		(0.01	)		(0.02	)

BALANCE_SHEET_DETAILS

BALANCE SHEET DETAILS	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Supplemental Balance Sheet Disclosures [Text Block]	'
	4	BALANCE SHEET DETAILS
	Accrued expenses:
			As of
			September 30,		December 31,
			2014		2013
	Accrued compensation and related benefits		$	276	$	266
	Series D convertible preferred dividend payable			26		26
	Total		$	302	$	292
	Related party liabilities:
			As of
			September 30,		December 31,
			2014		2013
	Promissory note – 2% interest		$	222	$	222
	Accrued interest			29		26
	Total		$	251	$	248
	The above promissory note is due March 5, 2015. At the option of the Company, the note and the accrued interest owed can be converted into common stock of the Company based on the closing price of the Company’s common stock on the day of the conversion. The conversion price of the note and accrued interest on the promissory note as of September 30, 2014 was $0.0915 and would convert to approximately 2,743,000 shares.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	5	FAIR VALUE MEASUREMENTS
	The Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2014 and December 31, 2013, by level within the fair value hierarchy, are as follows:
	Fair Value Measurements at September 30, 2014
			Level 1			Level 2			Level 3			Total
	Derivative Liability		$	—		$	—		$	—		$	—
	Fair Value Measurements at December 31, 2013
			Level 1			Level 2			Level 3			Total
	Derivative Liability		$	—		$	—		$	5,859		$	5,859
	For certain convertible note obligations, the Company is required to measure and record a related derivative liability, representing the estimated fair value of any embedded conversion options. The following table provides a summary of changes in the fair value of the Company’s Level 3 financial liabilities from December 31, 2013 to September 30, 2014:
			Derivative
			Liability
	31-Dec-13		$	5,859
	Conversion of 8% senior convertible debentures to common stock(1)			-4,784
	Change in fair value			-666
	31-Mar-14			409
	Conversion of 8% senior convertible debentures to common stock(2)			-277
	Change in fair value			193
	30-Jun-14			325
	Conversion of 8% senior convertible debentures to common stock(3)			-442
	Change in fair value			117
	30-Sep-14		$	0
			-1	The $4,784 was offset against the debt discount of $1,693 for a net amount of $3,091 included in the statement of equity as result of the conversions of the convertible debt.
			-2	The $277 was offset against the debt discount of $47 for a net amount of $230 included in the statement of equity as result of the conversions of the convertible debt.
			-3	The $442 was offset against the debt discount of $36 for a net amount of $406 included in the statement of equity as result of the conversions of the convertible debt.
	The weighted average Black-Scholes inputs associated with the conversion of 8% senior convertible debentures is as follows:
			For the Three Months Ended,
			March 31,				June 30,				September 30,
			2014				2014				2014			Total
	Number of shares issued (000 omitted)			77,406				4,567				5,042			87,015
	Debenture principal		$	2,995			$	174			$	202		$	3,371
	Fair value of debenture at conversion		$	4,784			$	277			$	442		$	5,503
	Exercise Price		$	0.04			$	0.04			$	0.04
	Volatility			134	%			90	%			95	%
	Risk-free Rate			0.07	%			0.04	%			0.02	%
	Contractual Life			0.6				0.25				0.12
	Dividend Yield			0	%			0	%			0	%
	The weighted average Black-Scholes inputs associated with the valuation of 8% senior convertible debentures is as follows:
			As of
			March 31,				June 30,				September 30,
			2014				2014				2014 (1)
	Exercise Price		$	0.04			$	0.04			$	N/A
	Volatility			133	%			86	%			N/A	%
	Risk-free Rate			0.07	%			0.04	%			N/A	%
	Contractual Life			0.4				0.3				N/A
	Dividend Yield			0	%			0	%			N/A	%
		-1	All convertible debentures were converted as of September 30, 2014

NET_LOSS_PER_SHARE

NET LOSS PER SHARE	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	6	NET LOSS PER SHARE
	The following table sets forth the computation of the basic and diluted net loss per share attributable to the Company’s common stockholders for the periods indicated:
			For the Three Months Ended				For the Nine Months Ended
			September 30,				September 30,
			2014		2013 (Restated)		2014		2013 (Restated)
	Numerator
	Net loss		$	-4,399	$	-3,040	$	-13,965	$	-8,875
	Preferred stock dividend			26		12		78		12
	Net loss attributable to common stockholders		$	-4,425	$	-3,052	$	-14,043	$	-8,887
	Denominator
	Weighted average shares outstanding during the period:
	Common stock - basic			767,657,531		478,883,561		711,302,222		415,163,655
	Common shares equivalents			—		—		—		—
	Common stock - diluted			767,657,531		478,883,561		711,302,222		415,163,655
	Net loss per share		$	-0.01	$	-0.01	$	-0.02	$	-0.02
	Potentially dilutive securities excluded from the computation of basic and dilutive net loss per share are as follows:
			As of September 30,
			2014		2013
	Outstanding time-based common stock options(1)			23,344,000		8,352,000
	Outstanding performance-based and market-based common stock options(1)			4,000,000		—
	Outstanding time-based preferred stock  options(1)			2,488,000		2,488,000
	Warrants(1)			46,637,000		84,553,000
	Related party liability(1)			2,743,000		3,918,000
	Convertible promissory note(1)			4,725,000		31,545,000
	Convertible preferred stock – Series C(1)			750,000		750,000
	Convertible preferred stock – Series D(1))			43,111,000		43,111,000
		-1	The impact of time-based, performance-based and market-based stock options, time-based restricted stock units, warrants, the convertible notes, the 8% senior convertible debentures, and the convertible preferred stock on earnings per share is anti-dilutive in a period of loss from continuing operations.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	7	INTANGIBLE ASSETS
	The following table summarizes our intangible assets:
			As of
			September 30,		December 31,
			2014		2013
	Intangible assets:
	Intellectual properties		$	1,685	$	681
	Accumulated amortization			-156		-70
	Total intangible assets net		$	1,529	$	611
	These intellectual properties costs will be amortized over the expected remaining useful lives. As of September 30, 2014, amortization expense for the next five years is expected to be as follows:
	2014 (three months)		$	33
	2015			128
	2016			128
	2017			128
	2018			128
	thereafter			984
	Total		$	1,529

8_SENIOR_CONVERTIBLE_DEBENTURE

8% SENIOR CONVERTIBLE DEBENTURES (8% Senior Convertible Debentures [Member])	9 Months Ended
	Sep. 30, 2014
8% Senior Convertible Debentures [Member]	'
Debt Disclosure [Text Block]	'
	8	8% Senior convertible debentures
	The following table summarizes the Company’s outstanding 8% convertible promissory note obligations:
				Stated
			Maturity	Interest				Principal Balance Outstanding
	Issue Date		Date	Rate			Conversion Terms	September 30, 2014		December 31, 2013
	10/2/13		10/2/14		8	%	Variable conversion price currently at $0.04	$	-	$	1,789
	9/6/13		9/6/14		8	%	Variable conversion price, currently at $0.04		-		1,544
			Sub total						-		3,333
			Discount						-		-2,401
			Current portion of 8% convertible promissory notes, net					$	-	$	932
	During the nine months ended September 30, 2014 approximately $3,458 consisting of approximately $3,333 of debentures and approximately $125 of accrued interest of the 8% senior convertible debentures were converted into 86,473,409 shares of common stock of the Company.  Additionally, $1,823 of the 8% senior convertible debentures related debt discount was reclassified from liability to additional paid in capital.

CONVERTIBLE_PROMISSORY_NOTES

CONVERTIBLE PROMISSORY NOTES (Convertible Promissory Notes Payable [Member])	9 Months Ended
	Sep. 30, 2014
Convertible Promissory Notes Payable [Member]	'
Debt Disclosure [Text Block]	'
	9	CONVERTIBLE PROMISSORY NOTES
	The following table summarizes the Company’s outstanding convertible promissory note obligations:
				Stated				Principal Balance Outstanding
				Interest				September 30,		December 31,
	Issue Date		Maturity Date	Rate			Conversion Terms	2014		2013
	6/5/13		12/2/13		6	%	Fixed at $0.02		-		20
	11/4/12		5/3/13		6	%	Fixed at $0.01		-		10
	8/23/12		2/19/13		6	%	Fixed at $0.015		-		50
	Nov-12		On Demand		None		Refundable excess payment		-		1
	6/6/11		6/6/13		5	%	Variable at $0.04		-		10
	4/11/11		4/11/13		5	%	Variable at $0.04		-		25
	5/1/11		5/1/13		5	%	Fixed at $0.10		-		4
	4/1/11		4/1/13		5	%	Fixed at $0.10		-		4
			Total convertible promissory notes					$	-	$	124
	Convertible notes converted to common stock or paid
	During the nine months ended September 30, 2014 an aggregate of approximately $115 in notes and $14 in accrued interest were converted into approximately 6,938,000 shares of common stock.
	During the nine months ended September 30, 2014 an aggregate of approximately $9 in notes and $1 in accrued interest were paid in full to the note holders

DEMAND_PROMISSORY_NOTE

DEMAND PROMISSORY NOTE (Demand Deposits [Member])	9 Months Ended
	Sep. 30, 2014
Demand Deposits [Member]	'
Debt Disclosure [Text Block]	'
		10	DEMAND PROMISSORY NOTE
	On February 14, 2014, the Company executed a Demand Promissory Note payable to Dominion Capital, LLC in the amount of $500 at an annual interest rate of 12% compounded monthly until the note is repaid. On March 12, 2014, the Company elected to extend the maturity of the Note from March 14, 2014 to August 14, 2014. On August 14, 2014 the note holder agreed to extend the due date thirty days for a consideration of $10 in cash to September 15, 2014. On September 12 2014 the note holder agreed to extend the due date thirty days for a consideration of $10 in common stock of the Company to October 15, 2014. On October 12 2014 the note holder agreed to extend the due date thirty days for a consideration of $10 in common stock of the Company to November 15, 2014.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	11	COMMITMENTS AND CONTINGENCIES
	Commitments:
	Lease Arrangements —
	The Company leases its main office facility and laboratory space in two separate locations in San Francisco.  During the three months ended September 30, 2014 the Company entered into a lease agreement and occupied office space at 655 Montgomery Street. The lease has a term which runs from August 2014 through November 2016 and provides for an initial monthly rental payment of $11,996.   Future minimum payments under this lease are:
	2014		(three months)	$	62
	2015				146
	2016				139
	Total			$	347
	The lease for the other research and development facility at 953 Indiana Street San Francisco, CA is a month-to-month lease at $6 per month commencing November 1, 2014.
	Rent expense for the three months ended September 30, 2014 and 2013 was $57 and $2 respectively, and for the nine months ended September 30, 2014 and 2013 was $120 and $14 respectively.
	Research Agreements —
	The Company and PGI Drug Discovery, LLC (“PGI”) entered into a services agreement on January 10,2014 pursuant to which PGI will provide certain services to the Company related to PGI’s proprietary analytical systems (refer to Note 7. INTANGIBLE ASSETS). The Company agreed to a payment commitment of $450 at a minimum annual rate of $150, for each of three years, to be paid each calendar quarter in equal installments. The Services Agreement is for a term of the later of 3 years or the completion of any study plan accepted by the parties under the services agreement.
	Pursuant to the December 12, 2013 license agreement between the Company and the University of Massachusetts, the Company is required to pay an annual license maintenance fee of $15 as long as the agreement remains in effect and the related patents remain valid. The Company is also obligated to reimburse the University for all patent costs incurred that are related to the licensed patents for the duration of the license agreement term.
	The Company and The Washington University (“WashU”) entered into a sponsored research agreement whereby the Company is required to pay a total amount of $120 for an employee of WashU to perform certain research utilizing a proprietary compound of the Company’s subject to certain terms and restrictions as further described in the Agreement.
	On August 5, 2014, the Company entered into a sponsored research agreement (the “Research Agreement”) with the Buck Institute for Research on Aging pursuant to which Dr. Heinrich Jasper shall perform certain research utilizing Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”), subject to certain terms and restrictions as further described in the Research Agreement.
	Pursuant to the Agreement, the Company shall provide financial support for the research plan, including four quarterly payments of $75, based upon the budget agreed to among the parties as set forth in the Agreement.
	On October 1 2014, the Company entered into a sponsored research agreement (the “Agreement”) with the University of Miami on the use of MANF in retinal disorders. The agreement calls for three equal payments of $52 on October 30, 2014, April 1, 2015 and upon receipt of the final written report.
	Service Agreements —
	On August 26, 2014 the “Company entered into a master services agreement (the “MSA”) with ICON Clinical Research Limited (“ICON”) pursuant to which the Company retained ICON to provide the Company with certain central laboratory services in connection with certain research studies. The services ordered will be set forth in work orders which will consist of a statement of work, a budget and a payment schedule. The agreement is for a term of four years unless terminated in accordance with its terms. The agreement calls for a Study Set-Up Fee of $85, and miscellaneous costs of $23, for a total commitment of $108
	Technical Acquisition —
	Pursuant to the MDx Purchase Agreement and contingent upon (i) the Company entering into a direct licensing agreement with the University of Leipzig (“Leipzig”) pursuant to which Leipzig would grant the Company a direct license to certain assets now licensed to MDx by Leipzig, and (ii) MDx terminating the license agreement it currently holds with Leipzig with the Company’s prior written consent, the Company has agreed to issue to MDx 6,500,000 shares of the Company’s common stock and will provide MDx with piggy-back registration rights as it relates to such shares.
	Contingencies:
	PGI
	On January 10, 2014, the Company entered into a license agreement (“PGI License Agreement”) with PGI Drug Discovery, LLC (“PGI”). Pursuant to the terms of the agreement, the Company agreed to pay PGI up to an aggregate of $4,000 in development milestones through NDA submission. Milestone based payments payable by the Company under the PGI License Agreement are as follows: (i) $1,000 upon successful completion of the first Phase 2b clinical study, and (ii) $3,000 upon submission of a New Drug Application with the United States Food and Drug Administration or a comparable submission outside of the United States.
	LPC
	Pursuant to the LPC Purchase Agreement (discussed in Note 13 – Common Stock Private Placements), the Company may be required to issue up to 3,500,000 shares of common stock to LPC on a pro rata basis if and when the Company utilizes funding available under the agreement.
	MDX
	Pursuant to the MDx Purchase Agreement and contingent upon (i) the Company entering into a direct licensing agreement with the University of Leipzig (“Leipzig”) pursuant to which Leipzig would grant the Company a direct license to certain assets now licensed to MDx by Leipzig, and (ii) MDx terminating the license agreement it currently holds with Leipzig with the Company’s prior written consent, the Company has agreed to issue to MDx 6,500,000 shares of the Company’s common stock and will provide MDx with piggy-back registration rights as it relates to such shares.
	UofM
	Pursuant to the December 12, 2013 license agreement between the Company and the University of Massachusetts (“UofM’), the Company is obligated to pay UofM certain amounts in the event certain events occur or milestones are achieved. Milestones to be paid under the agreement are as follows: (i) $50 upon first human dosing, (ii) $75 upon initiation of first Phase 2 clinical trial, (iii) $100 upon initiation of first Phase 3 clinical trial, and (iv) $500 upon first product approval in the United States. Following commercial launch, the Company is required to pay a royalty to the university equal to 2% of net sales, as defined under the agreement, subject to certain royalty minimums ranging from $125 to $500 per year. The Company is also obligated to pay to the university 10% of any sub-license income generated under the agreement.

COMMON_STOCK_WARRANTS

COMMON STOCK WARRANTS	9 Months Ended
	Sep. 30, 2014
Common Stock Warrants Abstract [Abstract]	'
Common Stock Warrants Disclosure [Text Block]	'
	12	COMMON STOCK WARRANTS
	Stock Warrants
	On March 7, 2014, the Company accepted elections by warrant holders to exercise certain warrants in the aggregate amount of 60,000,000 shares of common stock for gross proceeds of $3,600. Pursuant to the offer to exercise dated February 13, 2014 as supplemented on March 6, 2014, the holders of outstanding warrants to purchase shares of common stock of the Company at a price of $0.06 (the “Original Warrants”) were offered the opportunity to exercise their Original Warrants and receive warrants (the “New Warrants”) to purchase three (3) shares of common stock of the Company for every four (4) Original Warrants exercised. The New Warrants are exercisable at any time at a price of $0.12 for a term of five (5) years. The New Warrants are callable by the Company if the Volume Weighted Average Price (VWAP) of the Company’s common stock for each of 20 consecutive trading days exceeds $0.18 and certain equity conditions are met. The Company may also call the New Warrants if the closing price of the Company’s common stock exceeds $0.18 on the date that is the earlier of the receipt by the Company of an approval letter for listing of the Company’s common stock on an exchange or actual listing of the common stock on an exchange. The holders of the New Warrants have piggy-back registration rights. Upon the closing of the offer to exercise the Company issued New Warrants to purchase 45,000,000 shares of common stock of the Company.
	In the three months ended September 30, 2014, warrant holders exercised 20,138,810 warrants to purchase 20,138,810 shares of the Company’s common stock at the exercise price of $.06 per share for a total amount of approximately $1,208.
	In accordance with ASC 815-40-25-10 the Company determined that the appropriate accounting treatment of the New Warrants is to determine the fair value of the warrant and to record the fair value of the warrant as a loss upon Issuance of Warrants in the Other income (expense) section of the statement of operations along with a credit to Additional paid-In capital. The fair value was determined to be approximately $3,867, using the Black-Scholes model, which management believes approximates the fair value using the binomial lattice model with the following weighted average assumptions at issuance:
	Annualized volatility (1)		305	%
	Contractual term		5
	Risk-free investment rate		1.65	%
	Dividend yield		0	%
	(1) - The Company has three years of trading history that was utilized in computing the annualized volatility as of the date of issuance.
	The following table summarizes the Company’s warrant activity for the nine months ended September 30, 2014.
							Weighted Average
			Number of		Weighted Average		Remaining Contractual
			Warrants		Exercise Price		Term
	Outstanding warrants as of December 31, 2013			84,553,306		0.06		2.2
	Exercised			-82,916,584		0.06		2.2
	Issued			45,000,000		0.12		4.7
	Outstanding warrants as of September 30, 2014			46,636,722		0.1		4.3

COMMON_STOCK_PRIVATE_PLACEMENT

COMMON STOCK PRIVATE PLACEMENTS	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Common Stock Note Disclosure [Text Block]	'
	13	COMMON STOCK PRIVATE PLACEMENTS
	On March 7, 2014, the Company entered into an equity financing agreement (“LPC Purchase Agreement”) with Lincoln Park Capital Fund LLC (“LPC”) whereby LPC is obligated to purchase up to $20,000 of the Company’s common stock from time to time over a 30 month period, as directed by the Company and subject to certain requirements, restrictions and limitations. Under the LPC Purchase Agreement, the per share purchase price will be the lesser of (1) the lowest sale price of common stock on the purchase date and (2) the average of the three lowest closing purchase prices during the 10 consecutive business days prior to the purchase date. However, LPC is not obligated to purchase shares from the Company on any date that the closing price of the common stock is below $0.04, subject to adjustment upon the occurrence of certain stock related events. The Company may also request that LPC purchase shares under an accelerated purchase notice whereby the per share purchase price will be the lower of (i) 94% of a volume weighted average price calculation as determined under the LPC Purchase Agreement or (ii) the closing price of the common stock on the accelerated purchase date.
	In consideration for entering into the LPC Purchase Agreement, the Company agreed to issue 9,500,000 shares of common stock to LPC, 6,000,000 of which were issued upon entering into the agreement and 3,500,000 of which are contingently issuable on a pro rata basis as the Company utilizes the financing arrangement. The agreement will automatically terminate upon the earliest of 30 months or upon full utilization of the purchase commitment.
	Pursuant to the LPC Purchase Agreement, in the three months ended March 31, 2014 the Company sold an initial 4,000,000 shares to LPC for an aggregate gross purchase price of $400. The fair value of the 6,000,000 shares provided to LPC was approximately $516 and was treated as a deferred funding fee. $400 was considered a placement fee against the $400 raised pursuant to execution of the LPC Purchase Agreement. The remaining $116 of deferred funding fees will be offset against future capital raises.
	Also pursuant to the agreement, during the three months ended September 30, 2014, the Company sold an additional 9,000,000 shares for approximately $1,330 and issued an additional 232,785 commitment fee shares valued at $35 to LPC. The $35 commitment fee was charged to additional paid in capital in the three months ended September 30, 2014.

STOCK_OPTION_PLANS

STOCK OPTION PLANS	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
		14	STOCK OPTION PLANS
	2008 Stock Plan
	Under the Company’s 2008 Stock Plan (the “Plan”), the Company may grant up to 46,119,832, of incentive stock options, nonqualified stock options, or stock awards to eligible persons, including employees, nonemployees, and members of the Board of Directors, consultants, and other independent advisors who provide services to the Company. In general, options are granted with an exercise price equal to the fair value of the underlying common stock on the date of the grant. Options granted typically have a contractual life of 10 years and vest over periods ranging from being fully vested as of the grant date to four years.
	The following table is a summary of activity under the Plan:
									Outstanding
									Options
									Common
									Weighted
									Average
		Common Stock							Remaining
		options				Weighted Average			Contractual
		outstanding				Exercise Price			Term
	Balance – December 31, 2013			6,941,288			0.05			9
	Options granted (weighted-average fair value of $0.08)
	Employee			12,700,000			0.09			9.5
	Non-Employee			3,301,323			0.08			9.5
	Options cancelled			-1,000,000			0.08			—
	Options Exercised			—			—			—
	Balance –September 30, 2014			21,942,611			0.08			9.1
	Options vested as of September 30, 2014			13,496,489
	The 12,700,000 shares granted to employees include 8,000,000 shares granted to Robert Farrell, the Company’s Chief Financial Officer, 4,000,000 of which are time-based and vest 25 percent upon grant and 1/36 per month thereafter during continued service; 2,000,000 of which are performance-based and vest upon continued service and achievement of a specific goal; and 2,000,000 of which are market-based and vest upon continued service and the Company’s achievement of certain stock price targets. All of the 8,000,000 shares are at an exercise price of $0.0775 and were granted on March 31, 2014.
	During the nine months ended September 30, 2014, the company granted 2,301,323 net options (granted 3,301,323 less cancelled 1,000,000) to non-employees, resulting in an approximate expense of $93.
	2014 Stock Plan
	On August 6, 2014, the Company adopted the 2014 Stock Plan (the “2014 Plan”), which was approved by the Company’s stockholder at the Company’s Annual Meeting on September 22, 2014. Under the 2014 Plan, the Company may grant up to 153,380,168 common shares in the form of incentive stock options, nonqualified stock options or stock awards to eligible persons, including employees, nonemployees, members of the Board of Directors, consultants, and other independent advisors who provide services to the Company. In general, options are granted with an exercise price equal to the fair value of the underlying common stock on the date of the grant. Options granted typically have a contractual life of 10 years and vest over periods ranging from being fully vested as of the grant date to four years.
									Outstanding
									Options
									Common
									Weighted
									Average
		Common Stock							Remaining
		options				Weighted Average			Contractual
		outstanding				Exercise Price			Term
	Balance – December 31, 2013			-			-			-
	Options granted (weighted-average fair value of $0.09)
	Employee			5,400,000			0.09			10
	Non-Employee			—			—			—
	Options cancelled			—			—			—
	Options Exercised			—			—			—
	Balance –September 30, 2014			5,400,000			0.09			10
	Options vested as of September 30, 2014			84,791
	2012 Preferred Stock Plan
	In July 2012, our Board of Directors adopted the Management, Employee, Advisor and Director Preferred Stock Option Plan – 2012 Series B Convertible Preferred Stock Plan (“Preferred Stock Plan”). The purposes of the Preferred Stock Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to management, employees, advisors and directors and to promote the success of our business. Options granted under the Preferred Stock Plan currently vest over two or three years and cannot be converted into common shares or sold for two years from the date of the designation of the Series B Preferred shares. Each share of Series B Preferred stock converts into fifty shares of common stock. The following table is a summary of activity under the Preferred Stock Plan:
									Outstanding
									Preferred
									Options
									Weighted
									Average
				Preferred Stock					Remaining
				Options		Weighted Average			Contractual
				Outstanding		Exercise Price			Term
	Balance – December 31, 2013			2,287,500			0.47			8.5
	Options granted (weighted-average fair value of $1.61)
	Employee			200,000			2.21			9.3
	Non-Employee			—			—			—
	Options cancelled			—			—			—
	Balance – September 30, 2014			2,487,500			0.61			8.1
	Preferred options vested as of September 30, 2014			1,818,099
	Stock-based compensation expense for all plans is classified in the statements of operations as follows:
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2014			2013			2014		2013
	Research and development		$	124		$	64		$	311	$	366
	General and administrative			315			20			603		316
Total		$	439		$	84		$	914	$	682
At September 30, 2014, there was a total of approximately $1,620 of unrecognized compensation cost,  net of estimated forfeitures of zero, as the Company has not experienced any forfeitures to date, related to non-vested stock option awards, which is expected to be recognized over a weighted-average period of approximately 2.5 years.
The fair value of the Company’s stock-based awards during the nine months ended September 30, 2014 and 2013 were estimated using the Black-Scholes option-pricing model with the following approximate assumptions:
	Three Months Ended								Nine Months Ended
	September 30,								September 30,
	2014				2013				2014			2013
Weighted-average volatility			289	%			*	%		300	%		108	%
Weighted-average expected term			5.6				*			5.44			5
Expected dividends			0	%			*	%		0	%		0	%
Risk-free investment rate			1.89	%			*	%		1.9	%		0.5	%
* There were no options granted in the three months ended September 30, 2013

SERIES_D_PREFERRED_STOCK

SERIES D PREFERRED STOCK	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Preferred Stock [Text Block]	'
	15	SERIES D PREFERRED STOCK
	On June 30, 2014, with the approval of the holder of the Company’s Series D Preferred Stock, the Company filed an amendment to the Certificate of Designation of the Series D Preferred Stock to amend the terms of its Series D preferred stock to remove the feature by which stockholder could require redemption of the stock at cost. Accordingly, since the Series D Preferred Stock now contains mainly equity-like features, the Company changed the classification of the stock on its balance sheet from temporary equity to permanent equity within stockholders’ equity (deficit) as of June 30, 2014.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	16	SUBSEQUENT EVENTS
	Common Stock Private Placement
	In the period between October 1 2014 and November 3, 2014 2014, the Company exercised its rights under the LPC Purchase Agreement to sell 11,514,120 shares to LPC for a total of $885. As required by the agreement, the Company issued 154,855 commitment fee shares valued at $12 to LPC, which will be charged to additional paid in capital .

GENERAL_Policies

GENERAL (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Issued Accounting Pronouncements
	Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation removes all incremental financial reporting requirements for development stage entities, including the removal of reporting of the cumulative results of operations and cash flows for the period from inception to the end of the current period.  The update is effective for the first annual period beginning after December 15, 2014. Early adoption is permitted, and the Company has decided to adopt this change effective with its form 10-Q filing for the period ending June 30, 2014.
	Accounting Standard Update No. 2014-12, Compensation – stock requires that a performance target that affects vesting and that could be achieved after the requisite service period should be treated as a performance condition that affects vesting, rather than a condition that affects the grant-date fair value. The effective date will be for fiscal years, and interim periods within those years, beginning after December 15, 2015 for all entities. Early adoption is permitted. The Company is considering the effect of this FASB issuance, on the financial statements, and has decided not to early adopt at this time.
	Accounting Standard Update No. ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments in this update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.

RESTATEMENT_OF_PRIOR_QUARTERS_

RESTATEMENT OF PRIOR QUARTERS (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]	'
Restatement to Prior Year Income [Table Text Block]	'
	The following table sets forth the effects of the restatement on affected items within our previously reported Condensed Consolidated Statement of Operations for the three and nine months ended September 30, 2013.
		Three Months Ended						Nine Months Ended
		September 30, 2013						September 30, 2013
		As Reported			As Restated			As Reported			As Restated
	Operating loss	$	(679	)	$	(679	)	$	(3,868	)	$	(3,868	)
	Non-operating income (loss)		(1,347	)		(2,361	)		(1,916	)		(5,007	)
	Net loss		(2,026	)		(3,040	)		(5,784	)		(8,875	)
	Net loss per common share, basic and diluted		(0.00	)		(0.01	)		(0.01	)		(0.02	)

BALANCE_SHEET_DETAILS_Tables

BALANCE SHEET DETAILS (Tables)	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued expenses:
		As of
		September 30,		December 31,
		2014		2013
	Accrued compensation and related benefits	$	276	$	266
	Series D convertible preferred dividend payable		26		26
	Total	$	302	$	292
Schedule of Related Party Transactions [Table Text Block]	'
	Related party liabilities:
		As of
		September 30,		December 31,
		2014		2013
	Promissory note – 2% interest	$	222	$	222
	Accrued interest		29		26
	Total	$	251	$	248

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	The Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2014 and December 31, 2013, by level within the fair value hierarchy, are as follows:
	Fair Value Measurements at September 30, 2014
			Level 1			Level 2			Level 3			Total
	Derivative Liability		$	—		$	—		$	—		$	—
	Fair Value Measurements at December 31, 2013
			Level 1			Level 2			Level 3			Total
	Derivative Liability		$	—		$	—		$	5,859		$	5,859
Summary of Changes in the Fair value of the Companys Level 3 Financial Liability [Table Text Block]	'
	The following table provides a summary of changes in the fair value of the Company’s Level 3 financial liabilities from December 31, 2013 to September 30, 2014:
			Derivative
			Liability
	31-Dec-13		$	5,859
	Conversion of 8% senior convertible debentures to common stock(1)			-4,784
	Change in fair value			-666
	31-Mar-14			409
	Conversion of 8% senior convertible debentures to common stock(2)			-277
	Change in fair value			193
	30-Jun-14			325
	Conversion of 8% senior convertible debentures to common stock(3)			-442
	Change in fair value			117
	30-Sep-14		$	0
			-1	The $4,784 was offset against the debt discount of $1,693 for a net amount of $3,091 included in the statement of equity as result of the conversions of the convertible debt.
			-2	The $277 was offset against the debt discount of $47 for a net amount of $230 included in the statement of equity as result of the conversions of the convertible debt.
			-3	The $442 was offset against the debt discount of $36 for a net amount of $406 included in the statement of equity as result of the conversions of the convertible debt.
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]	'
	The weighted average Black-Scholes inputs associated with the conversion of 8% senior convertible debentures is as follows:
			For the Three Months Ended,
			March 31,				June 30,				September 30,
			2014				2014				2014			Total
	Number of shares issued (000 omitted)			77,406				4,567				5,042			87,015
	Debenture principal		$	2,995			$	174			$	202		$	3,371
	Fair value of debenture at conversion		$	4,784			$	277			$	442		$	5,503
	Exercise Price		$	0.04			$	0.04			$	0.04
	Volatility			134	%			90	%			95	%
	Risk-free Rate			0.07	%			0.04	%			0.02	%
	Contractual Life			0.6				0.25				0.12
	Dividend Yield			0	%			0	%			0	%
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	'
	The weighted average Black-Scholes inputs associated with the valuation of 8% senior convertible debentures is as follows:
			As of
			March 31,				June 30,				September 30,
			2014				2014				2014 (1)
	Exercise Price		$	0.04			$	0.04			$	N/A
	Volatility			133	%			86	%			N/A	%
	Risk-free Rate			0.07	%			0.04	%			N/A	%
	Contractual Life			0.4				0.3				N/A
	Dividend Yield			0	%			0	%			N/A	%
		-1	All convertible debentures were converted as of September 30, 2014

NET_LOSS_PER_SHARE_Tables

NET LOSS PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following table sets forth the computation of the basic and diluted net loss per share attributable to the Company’s common stockholders for the periods indicated:
			For the Three Months Ended				For the Nine Months Ended
			September 30,				September 30,
			2014		2013 (Restated)		2014		2013 (Restated)
	Numerator
	Net loss		$	-4,399	$	-3,040	$	-13,965	$	-8,875
	Preferred stock dividend			26		12		78		12
	Net loss attributable to common stockholders		$	-4,425	$	-3,052	$	-14,043	$	-8,887
	Denominator
	Weighted average shares outstanding during the period:
	Common stock - basic			767,657,531		478,883,561		711,302,222		415,163,655
	Common shares equivalents			—		—		—		—
	Common stock - diluted			767,657,531		478,883,561		711,302,222		415,163,655
	Net loss per share		$	-0.01	$	-0.01	$	-0.02	$	-0.02
	Potentially dilutive securities excluded from the computation of basic and dilutive net loss per share are as follows:
			As of September 30,
			2014		2013
	Outstanding time-based common stock options(1)			23,344,000		8,352,000
	Outstanding performance-based and market-based common stock options(1)			4,000,000		—
	Outstanding time-based preferred stock  options(1)			2,488,000		2,488,000
	Warrants(1)			46,637,000		84,553,000
	Related party liability(1)			2,743,000		3,918,000
	Convertible promissory note(1)			4,725,000		31,545,000
	Convertible preferred stock – Series C(1)			750,000		750,000
	Convertible preferred stock – Series D(1))			43,111,000		43,111,000
		-1	The impact of time-based, performance-based and market-based stock options, time-based restricted stock units, warrants, the convertible notes, the 8% senior convertible debentures, and the convertible preferred stock on earnings per share is anti-dilutive in a period of loss from continuing operations.

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	'
	The following table summarizes our intangible assets:
		As of
		September 30,		December 31,
		2014		2013
	Intangible assets:
	Intellectual properties	$	1,685	$	681
	Accumulated amortization		-156		-70
	Total intangible assets net	$	1,529	$	611
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	These intellectual properties costs will be amortized over the expected remaining useful lives. As of September 30, 2014, amortization expense for the next five years is expected to be as follows:
	2014 (three months)	$	33
	2015		128
	2016		128
	2017		128
	2018		128
	thereafter		984
	Total	$	1,529

8_SENIOR_CONVERTIBLE_DEBENTURE1

8% SENIOR CONVERTIBLE DEBENTURES (Tables) (8% Senior Convertible Debentures [Member])	9 Months Ended
	Sep. 30, 2014
8% Senior Convertible Debentures [Member]	'
Schedule of Debt [Table Text Block]	'
	The following table summarizes the Company’s outstanding 8% convertible promissory note obligations:
			Stated
		Maturity	Interest				Principal Balance Outstanding
	Issue Date	Date	Rate			Conversion Terms	September 30, 2014		December 31, 2013
	10/2/13	10/2/14		8	%	Variable conversion price currently at $0.04	$	-	$	1,789
	9/6/13	9/6/14		8	%	Variable conversion price, currently at $0.04		-		1,544
		Sub total						-		3,333
		Discount						-		-2,401
		Current portion of 8% convertible promissory notes, net					$	-	$	932

CONVERTIBLE_PROMISSORY_NOTES_T

CONVERTIBLE PROMISSORY NOTES (Tables) (Convertible Promissory Notes Payable [Member])	9 Months Ended
	Sep. 30, 2014
Convertible Promissory Notes Payable [Member]	'
Schedule of Debt [Table Text Block]	'
	The following table summarizes the Company’s outstanding convertible promissory note obligations:
			Stated				Principal Balance Outstanding
			Interest				September 30,		December 31,
	Issue Date	Maturity Date	Rate			Conversion Terms	2014		2013
	6/5/13	12/2/13		6	%	Fixed at $0.02		-		20
	11/4/12	5/3/13		6	%	Fixed at $0.01		-		10
	8/23/12	2/19/13		6	%	Fixed at $0.015		-		50
	Nov-12	On Demand		None		Refundable excess payment		-		1
	6/6/11	6/6/13		5	%	Variable at $0.04		-		10
	4/11/11	4/11/13		5	%	Variable at $0.04		-		25
	5/1/11	5/1/13		5	%	Fixed at $0.10		-		4
	4/1/11	4/1/13		5	%	Fixed at $0.10		-		4
		Total convertible promissory notes					$	-	$	124

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	Future minimum payments under this lease are:
	2014	(three months)	$	62
	2015			146
	2016			139
	Total		$	347

COMMON_STOCK_WARRANTS_Tables

COMMON STOCK WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2014
Common Stock Warrants Abstract [Abstract]	'
Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]	'
	The fair value was determined to be approximately $3,867, using the Black-Scholes model, which management believes approximates the fair value using the binomial lattice model with the following weighted average assumptions at issuance:
	Annualized volatility (1)	305	%
	Contractual term	5
	Risk-free investment rate	1.65	%
	Dividend yield	0	%
	(1) - The Company has three years of trading history that was utilized in computing the annualized volatility as of the date of issuance.
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	The following table summarizes the Company’s warrant activity for the nine months ended September 30, 2014.
						Weighted Average
		Number of		Weighted Average		Remaining Contractual
		Warrants		Exercise Price		Term
	Outstanding warrants as of December 31, 2013		84,553,306		0.06		2.2
	Exercised		-82,916,584		0.06		2.2
	Issued		45,000,000		0.12		4.7
	Outstanding warrants as of September 30, 2014		46,636,722		0.1		4.3

STOCK_OPTION_PLANS_Tables

STOCK OPTION PLANS (Tables)	9 Months Ended
	Sep. 30, 2014
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	Stock-based compensation expense for all plans is classified in the statements of operations as follows:
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2014			2013			2014		2013
	Research and development		$	124		$	64		$	311	$	366
	General and administrative			315			20			603		316
	Total		$	439		$	84		$	914	$	682
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The fair value of the Company’s stock-based awards during the nine months ended September 30, 2014 and 2013 were estimated using the Black-Scholes option-pricing model with the following approximate assumptions:
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2014				2013				2014			2013
	Weighted-average volatility			289	%			*	%		300	%		108	%
	Weighted-average expected term			5.6				*			5.44			5
	Expected dividends			0	%			*	%		0	%		0	%
	Risk-free investment rate			1.89	%			*	%		1.9	%		0.5	%
	* There were no options granted in the three months ended September 30, 2013
Stock Plan 2008 [Member]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table is a summary of activity under the Plan:
									Outstanding
									Options
									Common
									Weighted
									Average
		Common Stock							Remaining
		options				Weighted Average			Contractual
		outstanding				Exercise Price			Term
	Balance – December 31, 2013			6,941,288			0.05			9
	Options granted (weighted-average fair value of $0.08)
	Employee			12,700,000			0.09			9.5
	Non-Employee			3,301,323			0.08			9.5
	Options cancelled			-1,000,000			0.08			—
	Options Exercised			—			—			—
	Balance –September 30, 2014			21,942,611			0.08			9.1
	Options vested as of September 30, 2014			13,496,489
Stock Plan 2014 [Member]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
									Outstanding
									Options
									Common
									Weighted
									Average
		Common Stock							Remaining
		options				Weighted Average			Contractual
		outstanding				Exercise Price			Term
	Balance – December 31, 2013			-			-			-
	Options granted (weighted-average fair value of $0.09)
	Employee			5,400,000			0.09			10
	Non-Employee			—			—			—
	Options cancelled			—			—			—
	Options Exercised			—			—			—
	Balance –September 30, 2014			5,400,000			0.09			10
	Options vested as of September 30, 2014			84,791
Preferred Stock Plan 2012 [Member]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table is a summary of activity under the Preferred Stock Plan:
									Outstanding
									Preferred
									Options
									Weighted
									Average
				Preferred Stock					Remaining
				Options		Weighted Average			Contractual
				Outstanding		Exercise Price			Term
	Balance – December 31, 2013			2,287,500			0.47			8.5
	Options granted (weighted-average fair value of $1.61)
	Employee			200,000			2.21			9.3
	Non-Employee			—			—			—
	Options cancelled			—			—			—
	Balance – September 30, 2014			2,487,500			0.61			8.1
	Preferred options vested as of September 30, 2014			1,818,099

LIQUIDITY_AND_GOING_CONCERN_De

LIQUIDITY AND GOING CONCERN (Details Textual) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Liquidity And Going Concern [Line Items]	'	'	'	'
Cash and cash equivalents	$680	$1,033	$1,105	$157

RESTATEMENT_OF_PRIOR_QUARTERS_1

RESTATEMENT OF PRIOR QUARTERS (Details) (USD $)	3 Months Ended				9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Operating loss	($3,969)	'	'	($679)	($9,345)	($3,868)
Non-operating income (loss)	-430	'	'	-2,361	-4,620	-5,007
Net loss	-4,399	-4,025	-5,542	-3,040	-13,965	-8,875
Net loss per common share, basic and diluted (in dollar per share)	($0.01)	'	'	($0.01)	($0.02)	($0.02)
Scenario, Previously Reported [Member]	'	'	'	'	'	'
Operating loss	'	'	'	-679	'	-3,868
Non-operating income (loss)	'	'	'	-1,347	'	-1,916
Net loss	'	'	'	-2,026	'	-5,784
Net loss per common share, basic and diluted (in dollar per share)	'	'	'	$0	'	($0.01)
Restatement Adjustment [Member]	'	'	'	'	'	'
Operating loss	'	'	'	-679	'	-3,868
Non-operating income (loss)	'	'	'	-2,361	'	-5,007
Net loss	'	'	'	($3,040)	'	($8,875)
Net loss per common share, basic and diluted (in dollar per share)	'	'	'	($0.01)	'	($0.02)

BALANCE_SHEET_DETAILS_Details

BALANCE SHEET DETAILS (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Details [Line Items]	'	'
Total	$302	$292
Accrued Compensation And Related Benefits [Member]	'	'
Balance Sheet Details [Line Items]	'	'
Total	276	266
Series D Convertible Preferred dividend payable [Member]	'	'
Balance Sheet Details [Line Items]	'	'
Total	$26	$26

BALANCE_SHEET_DETAILS_Details_

BALANCE SHEET DETAILS (Details 1) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Details [Line Items]	'	'
Total	$251	$248
Promissory Notes Payable [Member]	'	'
Balance Sheet Details [Line Items]	'	'
Total	222	222
Accrued Interest [Member]	'	'
Balance Sheet Details [Line Items]	'	'
Total	$29	$26

BALANCE_SHEET_DETAILS_Details_1

BALANCE SHEET DETAILS (Details Textual) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014
			Promissory Notes Payable [Member]
Balance Sheet Details [Line Items]	'	'	'
Debt Instrument, Maturity Date	'	'	5-Mar-15
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%	2.00%
Debt Instrument, Convertible, Conversion Price	'	'	$0.09
Debt Conversion, Converted Instrument, Shares Issued	'	'	2,743,000

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Derivative Liability	$0	$325	$409	$5,859
Fair Value, Inputs, Level 1 [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Derivative Liability	0	'	'	0
Fair Value, Inputs, Level 2 [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Derivative Liability	0	'	'	0
Fair Value, Inputs, Level 3 [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Derivative Liability	$0	'	'	$5,859

FAIR_VALUE_MEASUREMENTS_Detail1

FAIR VALUE MEASUREMENTS (Details 1) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014		Jun. 30, 2014		Mar. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'		'
Balance	$325		$409		$5,859
Conversion of 8% senior convertible debentures to common stock	-442	[1]	-277	[2]	-4,784	[3]
Change in fair value	117		193		-666
Balance	$0		$325		$409
[1]	The $442 was offset against the debt discount of $36 for a net amount of $406 included in the statement of equity as result of the conversions of the convertible debt.
[2]	The $277 was offset against the debt discount of $47 for a net amount of $230 included in the statement of equity as result of the conversions of the convertible debt.
[3]	The $4,784 was offset against the debt discount of $1,693 for a net amount of $3,091 included in the statement of equity as result of the conversions of the convertible debt.

FAIR_VALUE_MEASUREMENTS_Detail2

FAIR VALUE MEASUREMENTS (Details 2) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended			9 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2014
					Senior Convertible Debentures 8 [Member]	Senior Convertible Debentures 8 [Member]	Senior Convertible Debentures 8 [Member]	Senior Convertible Debentures 8 [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'	'	'	'	'	'	'
Number of shares issued (000 omitted)	'	'	'	'	5,042	4,567	77,406	87,015
Debenture principal	'	'	'	'	$202	$174	$2,995	$3,371
Fair value of debenture at conversion	'	'	$11	$1,198	$442	$277	$4,784	$5,503
Exercise Price	$0.04	$0.04	'	'	$0.04	$0.04	$0.04	$0.04
Volatility	86.00%	133.00%	'	'	95.00%	90.00%	134.00%	'
Risk-free Rate	0.04%	0.07%	'	'	0.02%	0.04%	0.07%	'
Contractual Life	'3 months 18 days	'4 months 24 days	'	'	'1 month 13 days	'3 months	'7 months 6 days	'
Dividend Yield	0.00%	0.00%	'	'	0.00%	0.00%	0.00%	'

FAIR_VALUE_MEASUREMENTS_Detail3

FAIR VALUE MEASUREMENTS (Details 3) (USD $)	3 Months Ended
	Jun. 30, 2014	Mar. 31, 2014
Contractual Life	'	'
Exercise Price	$0.04	$0.04
Volatility	86.00%	133.00%
Risk-free Rate	0.04%	0.07%
Contractual Life	'3 months 18 days	'4 months 24 days
Dividend Yield	0.00%	0.00%

FAIR_VALUE_MEASUREMENTS_Detail4

FAIR VALUE MEASUREMENTS (Details Textual) (USD $)	3 Months Ended			9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	8.00%	'	'	8.00%	'	8.00%
Debt Conversion, Converted Instrument, Amount	'	'	'	$11	$1,198	'
Stock Issued During Period, Value, Issued Upon Conversion Of Senior Convertible Debt	180	182	3,091	'	'	'
8% Senior Convertible Debentures [Member]	'	'	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	8.00%	'	'	8.00%	'	'
Debt Conversion, Converted Instrument, Amount	442	277	4,784	5,503	'	'
Debt Instrument, Unamortized Discount	36	47	1,693	36	'	'
Stock Issued During Period, Value, Issued Upon Conversion Of Senior Convertible Debt	$406	$230	$3,091	'	'	'

NET_LOSS_PER_SHARE_Details

NET LOSS PER SHARE (Details) (USD $)	3 Months Ended				9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Sep. 30, 2014		Sep. 30, 2013
Numerator	'	'	'	'	'		'
Net loss	($4,399)	($4,025)	($5,542)	($3,040)	($13,965)		($8,875)
Preferred stock dividend	26	'	'	12	78		12
Net loss attributable to common stockholders	($4,425)	'	'	($3,052)	($14,043)		($8,887)
Denominator	'	'	'	'	'		'
Common stock - basic (in shares)	767,657,531	'	'	478,883,561	711,302,222		415,163,655
Common shares equivalents (in shares)	0	'	'	0	0		0
Common stock - diluted (in shares)	767,657,531	'	'	478,883,561	711,302,222		415,163,655
Net loss per share (in dollars per share)	($0.01)	'	'	($0.01)	($0.02)		($0.02)
Potentially dilutive securities:	'	'	'	'	'		'
Outstanding time-based common stock options	'	'	'	'	23,344,000	[1]	8,352,000	[1]
Outstanding performance-based and market-based common stock options	'	'	'	'	4,000,000	[1]	0	[1]
Outstanding time-based preferred stock options	'	'	'	'	2,488,000	[1]	2,488,000	[1]
Warrants	'	'	'	'	46,637,000	[1]	84,553,000	[1]
Related party liability	'	'	'	'	2,743,000	[1]	3,918,000	[1]
Convertible promissory note	'	'	'	'	4,725,000	[1]	31,545,000	[1]
Series C Preferred Stock [Member]	'	'	'	'	'		'
Potentially dilutive securities:	'	'	'	'	'		'
Convertible preferred stock	'	'	'	'	750,000	[1]	750,000	[1]
Series D Preferred Stock [Member]	'	'	'	'	'		'
Potentially dilutive securities:	'	'	'	'	'		'
Convertible preferred stock	'	'	'	'	43,111,000	[1]	43,111,000	[1]
[1]	The impact of time-based, performance-based and market-based stock options, time-based restricted stock units, warrants, the convertible notes, the 8% senior convertible debentures, and the convertible preferred stock on earnings per share is anti-dilutive in a period of loss from continuing operations.

NET_LOSS_PER_SHARE_Details_Tex

NET LOSS PER SHARE (Details Textual)	Sep. 30, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Intangible assets:	'	'
Intellectual properties	$1,685	$681
Accumulated amortization	-156	-70
Total intangible assets net	$1,529	$611

INTANGIBLE_ASSETS_Details_1

INTANGIBLE ASSETS (Details 1) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
2014 (three months)	$33	'
2015	128	'
2016	128	'
2017	128	'
2018	128	'
thereafter	984	'
Total	$1,529	$611

8_SENIOR_CONVERTIBLE_DEBENTURE2

8% SENIOR CONVERTIBLE DEBENTURES (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified			8% Senior Convertible Debenture Issuance One [Member]	8% Senior Convertible Debenture Issuance One [Member]	8% Senior Convertible Debenture Issuance Two [Member]	8% Senior Convertible Debenture Issuance Two [Member]	8% Senior Convertible Debenture Issuance One And Two [Member]	8% Senior Convertible Debenture Issuance One And Two [Member]	8% Senior Convertible Debentures [Member]	8% Senior Convertible Debentures [Member]	8% Senior Convertible Debentures [Member]
Debt Instrument, Redemption [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Issue Date	'	'	2-Oct-13	'	6-Sep-13	'	'	'	'	'	'
Maturity Date	'	'	2-Oct-14	'	6-Sep-14	'	'	'	'	'	'
Stated Interest Rate	8.00%	8.00%	8.00%	'	8.00%	'	'	'	8.00%	'	'
Conversion Terms	'	'	'Variable conversion price currently at $0.04	'	'Variable conversion price, currently at $0.04	'	'	'	'	'	'
Long-term Debt, Gross	$0	$3,333	$0	$1,789	$0	$1,544	'	'	'	'	'
Discount	'	'	'	'	'	'	0	-2,401	-36	-47	-1,693
Current portion of 8% convertible promissory notes, net of debt discount	$0	$932	'	'	'	'	'	'	'	'	'

8_SENIOR_CONVERTIBLE_DEBENTURE3

8% SENIOR CONVERTIBLE DEBENTURES (Details Textual) (USD $)	3 Months Ended			9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2014
Senior Debt Obligations [Member]	'	'	'	'
Debt Instrument, Redemption [Line Items]	'	'	'	'
Debt Conversion, Converted Instrument, Rate	'	'	'	8.00%
8% Senior Convertible Debentures [Member]	'	'	'	'
Debt Instrument, Redemption [Line Items]	'	'	'	'
Debt Conversion Converted Instrument Amount Including Interest	'	'	'	$3,458
Debt Conversion, Converted Instrument, Principal Amount	'	'	'	3,333
Debt Conversion, Converted Instrument, Accrued Interest Amount	'	'	'	125
Debt Conversion, Converted Instrument, Rate	'	'	'	8.00%
Debt Conversion, Converted Instrument, Shares Issued	5,042	4,567	77,406	87,015
Debt Discount Written Off, Convertible Promissory Notes	'	'	'	$1,823
8% Senior Convertible Debentures [Member] | Common Stock [Member]	'	'	'	'
Debt Instrument, Redemption [Line Items]	'	'	'	'
Debt Conversion, Converted Instrument, Shares Issued	'	'	'	86,473,409

CONVERTIBLE_PROMISSORY_NOTES_D

CONVERTIBLE PROMISSORY NOTES (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Long-term Debt, Gross	$0	$3,333
Total convertible promissory notes	0	124
Convertible Promissory Notes Payable Issuance One [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	5-Jun-13	'
Debt Instrument, Maturity Date	2-Dec-13	'
Debt Instrument, Interest Rate, Stated Percentage	6.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.02	'
Long-term Debt, Gross	0	20
Convertible Promissory Notes Payable Issuance Two [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	4-Nov-12	'
Debt Instrument, Maturity Date	3-May-13	'
Debt Instrument, Interest Rate, Stated Percentage	6.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.01	'
Long-term Debt, Gross	0	10
Convertible Promissory Notes Payable Issuance Three [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	23-Aug-12	'
Debt Instrument, Maturity Date	19-Feb-13	'
Debt Instrument, Interest Rate, Stated Percentage	6.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.015	'
Long-term Debt, Gross	0	50
Convertible Promissory Notes Payable Issuance Four [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	1-Nov-12	'
Debt Instrument Maturity	'On Demand	'
Debt Instrument, Interest Rate, Stated Percentage	0.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Refundable excess payment	'
Long-term Debt, Gross	0	1
Convertible Promissory Notes Payable Issuance Five [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	6-Jun-11	'
Debt Instrument, Maturity Date	6-Jun-13	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Variable at $0.04	'
Long-term Debt, Gross	0	10
Convertible Promissory Notes Payable Issuance Six [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	11-Apr-11	'
Debt Instrument, Maturity Date	11-Apr-13	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Variable at $0.04	'
Long-term Debt, Gross	0	25
Convertible Promissory Notes Payable Issuance Seven [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	1-May-11	'
Debt Instrument, Maturity Date	1-May-13	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.10	'
Long-term Debt, Gross	0	4
Convertible Promissory Notes Payable Issuance Eight [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	1-Apr-11	'
Debt Instrument, Maturity Date	1-Apr-13	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.10	'
Long-term Debt, Gross	$0	$4

CONVERTIBLE_PROMISSORY_NOTES_D1

CONVERTIBLE PROMISSORY NOTES (Details Textual) (USD $)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Debt Instrument [Line Items]	'	'
Repayment of borrowings	$0	$3
Convertible Notes Payable [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Conversion, Original Debt, Amount	115	'
Debt Conversion Accrued Interest Amount	14	'
Debt Conversion, Converted Instrument, Shares Issued	6,938,000	'
Repayment of borrowings	9	'
Payment Of Accrued Interest Notes Payable	$1	'

DEMAND_PROMISSORY_NOTE_Details

DEMAND PROMISSORY NOTE (Details Textual) (USD $)	0 Months Ended				9 Months Ended
In Thousands, unless otherwise specified	Sep. 12, 2014	Aug. 14, 2014	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014
					Subsequent Event [Member]	Dominion Capital, LLC. [Member]
Demand Promissory Notes [Line Items]	'	'	'	'	'	'
Demand Promissory Notes, Current	'	'	$500	$0	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	8.00%	8.00%	'	12.00%
Payments To Be Made Extend Debt Maturity Date	$10	$10	'	'	$10	'

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Operating Leases Future Minimum Payments [Line Items]	'
2014 (three months)	$62
2015	146
2016	139
Total	$347

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

9 Months Ended

1 Months Ended

0 Months Ended

In Thousands, except Share data, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jan. 10, 2014

Jan. 10, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Aug. 31, 2014

Aug. 31, 2014

Aug. 31, 2014

Jan. 10, 2014

University of Massachusetts License [Member]

University of Massachusetts License [Member]

University of Massachusetts License [Member]

Maximum [Member]

Minimum [Member]

MDx Purchase Agreement [Member]

PGI License Agreement [Member]

PGI License Agreement [Member]

Research And Development Facility Agreement [Member]

Research and Development Arrangement [Member]

Research and Development Arrangement [Member]

Research and Development Arrangement [Member]

Master Service Agreement [Member]

Master Service Agreement [Member]

Master Service Agreement [Member]

LPC Purchase Agreement [Member]

Sales Revenue, Net [Member]

Sub-license Income [Member]

University of Massachusetts License [Member]

University of Massachusetts License [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Set-Up Fee [Member]

Miscellaneous Costs [Member]

Call For October 2014 [Member]

Call For April 2014 [Member]

Call For Subsequent Period [Member]

Loss Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease Rental Payments, Per Month

'

'

'

'

'

'

'

'

'

'

'

'

'

$6

'

'

'

'

'

'

'

Operating Leases, Rent Expense

57

2

120

14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

License Costs

'

'

'

'

'

15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Acquisitions

'

'

'

'

'

'

'

'

'

'

6,500,000

'

'

'

'

'

'

'

'

'

3,500,000

Concentration Risk, Percentage

'

'

'

'

'

'

2.00%

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty Expense

'

'

'

'

'

'

'

'

500

125

'

'

'

'

'

'

'

'

'

'

'

Payment Of License Agreement Milestone Development Cost

'

'

'

'

'

'

'

'

'

'

'

4,000

'

'

'

'

'

'

'

'

'

Payment of License Agreement Milestone Development Cost upon Completion

'

'

'

'

'

'

'

'

'

'

'

1,000

'

'

'

'

'

'

'

'

'

Payment of License Agreement Milestone Development Cost upon Submission of Drug Application

'

'

'

'

'

'

'

'

'

'

'

3,000

'

'

'

'

'

'

'

'

'

Operating Leases, Future Minimum Payments Due, Total

347

'

347

'

'

'

'

'

'

'

'

'

450

'

'

'

'

'

'

'

'

Operating Leases, Future Minimum Payments, Remainder of Fiscal Year

62

'

62

'

'

'

'

'

'

'

'

'

150

'

'

'

'

'

'

'

'

Operating Leases, Future Minimum Payments, Due in Two Years

146

'

146

'

'

'

'

'

'

'

'

'

150

'

'

'

'

'

'

'

'

Operating Leases, Future Minimum Payments, Due in Three Years

139

'

139

'

'

'

'

'

'

'

'

'

150

'

'

'

'

'

'

'

'

Lessee Leasing Arrangements, Operating Leases, Term of Contract

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

Milestone Agreement Payment Description

'

'

'

'

'

'Milestones to be paid under the agreement are as follows: (i) $50 upon first human dosing, (ii) $75 upon initiation of first Phase 2 clinical trial, (iii) $100 upon initiation of first Phase 3 clinical trial, and (iv) $500 upon first product approval in the United States

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments Required To Perform Research Activity

'

'

'

'

120

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Quarterly Payments Required To Perform Research Activity

'

'

75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development

1,899

289

4,056

1,427

'

'

'

'

'

'

'

'

'

'

52

52

52

108

85

23

'

Initial Monthly Rental Payment

'

'

$11,996

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

COMMON_STOCK_WARRANTS_Details

COMMON STOCK WARRANTS (Details)	3 Months Ended		9 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2014
			Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'
Annualized volatility	'	'	305.00%	[1]
Contractual term	'3 months 18 days	'4 months 24 days	'5 years
Risk-free investment rate	0.04%	0.07%	1.65%
Dividend yield	0.00%	0.00%	0.00%
[1]	The Company has three years of trading history that was utilized in computing the annualized volatility as of the date of issuance.

COMMON_STOCK_WARRANTS_Details_

COMMON STOCK WARRANTS (Details 1) (USD $)	0 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 07, 2014	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
		Warrant [Member]	Warrant [Member]	Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Outstanding Balance - Beginning	'	'	84,553,306	'
Number of Warrants Exercised (in shares)	-60,000,000	-20,138,810	-82,916,584	'
Number of Warrants Issued (in shares)	'	'	45,000,000	'
Outstanding Balance - Ending	'	46,636,722	46,636,722	84,553,306
Weighted Average Exercise Price - Beginning Balance	'	'	$0.06	'
Weighted Average Exercise Price - Exercised	'	$0.06	$0.06	'
Weighted Average Exercise Price - Expired	'	'	$0.12	'
Weighted Average Exercise Price - Ending Balance	'	$0.10	$0.10	$0.06
Weighted Average Remaining Contractual Term-Balance	'	'	'4 years 3 months 18 days	'2 years 2 months 12 days
Exercised Weighted Average Remaining Contractual Term - Exercised	'	'	'2 years 2 months 12 days	'
Exercised Weighted Average Remaining Contractual Term - Issued	'	'	'4 years 8 months 12 days	'

COMMON_STOCK_WARRANTS_Details_1

COMMON STOCK WARRANTS (Details Textual) (USD $)	0 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 07, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
			Warrant [Member]	Warrant [Member]	New Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	60,000,000	'	20,138,810	82,916,584	'
Proceeds from Warrant Exercises	$3,600	'	'	'	'
Warrant To Purchase Of Common Stock Exercised Description	'	'Pursuant to the offer to exercise dated February 13, 2014 as supplemented on March 6, 2014, the holders of outstanding warrants to purchase shares of common stock of the Company at a price of $0.06 (the Original Warrants) were offered the opportunity to exercise their Original Warrants and receive warrants (the New Warrants) to purchase three (3) shares of common stock of the Company for every four (4) Original Warrants exercised	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.12	'	$0.06	$0.06	'
Common Stock Warrants Closing Price Per Share	$0.18	'	'	'	'
Fair Value Adjustment of Warrants	'	3,867	'	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	'	'	$0.06	$0.06	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	'	'	$1,208	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	'	'	'	45,000,000

COMMON_STOCK_PRIVATE_PLACEMENT1

COMMON STOCK PRIVATE PLACEMENTS (Details Textual) (USD $)	3 Months Ended		9 Months Ended	1 Months Ended	75 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 07, 2014
				LPC Purchase Agreement [Member]	LPC Purchase Agreement [Member]	LPC Purchase Agreement [Member]
Common Stock [Line Items]	'	'	'	'	'	'
Stock Purchase Agreement Description	'	'	'the per share purchase price will be the lesser of (1) the lowest sale price of common stock on the purchase date and (2) the average of the three lowest closing purchase prices during the 10 consecutive business days prior to the purchase date.	'	'	'
Equity Financing Agreement Term	'	'	'	'30 months	'	'
Percentage of Weighted Average Price Determined Under Equity Financing Agreement	'	'	'	94.00%	'	'
Shares Obligated to Purchase Under Equity Financing Agreement	'	'	'	'	'	9,500,000
Shares Issuable upon Entering into Equity Financing Agreement	'	'	'	'	'	6,000,000
Shares Contingently Issuable Under Equity Financing Agreement	'	'	'	'	'	3,500,000
Shares Issued Under Equity Financing Agreement, Shares	'	'	'	4,000,000	4,000,000	'
Shares Issued Under Equity Financing Agreement, Value	'	'	'	$400	'	'
Value Of Shares Obligated to Purchase Under Equity Financing Agreement	'	'	'	'	'	20,000
Shares Issuable Upon Entering Into Equity Financing Agreement Treated As Deferred Funding Fee	'	'	'	'	'	6,000,000
Value Of Shares Issuable Upon Entering Into Equity Financing Agreement Treated As Deferred Funding Fee	'	'	'	'	'	516
Fees and Commissions	'	'	'	'	400	'
Deferred Funding Fees Offset Against Future Capital Raises	'	'	'	'	'	116
Common stock issued for purchase under stock purchase agreement (in shares)	9,000,000	'	'	'	'	'
Common stock issued as consideration for stock purchase agreement	1,330	'	'	'	'	'
Common stock issued as consideration for stock purchase agreement (in shares)	232,785	'	'	'	'	'
Stock pursuant agreement, deferred commitment fees	35	'	'	'	'	'
Adjustments To Additional Paid In Capital Deferred Funding Costs Charged To Equity Upon Sale Of Common Stock	$35	($400)	$400	'	'	'

STOCK_OPTION_PLANS_Details

STOCK OPTION PLANS (Details) (USD $)	0 Months Ended	9 Months Ended	12 Months Ended
	Mar. 07, 2014	Sep. 30, 2014	Dec. 31, 2013
		2008 Stock Plan [Member]	2008 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Outstanding Balance - Beginning	'	6,941,288	'
Common Stock Option Outstanding - Options granted Employees	'	12,700,000	'
Common Stock Option Outstanding - Options granted Non-Employee	'	3,301,323	'
Common Stock Option Outstanding - Options Cancelled	'	-1,000,000	'
Common Stock Option Outstanding - Options Exercised	-60,000,000	0	'
Outstanding Balance - Ending	'	21,942,611	6,941,288
Options vested as of September 30, 2014	'	13,496,489	'
Weighted Average Exercise Price - Beginning Balance	'	$0.05	'
Weighted Average Exercise Price - Options granted Employee	'	$0.09	'
Weighted Average Exercise Price - Options granted Non-Employee	'	$0.08	'
Weighted Average Exercise Price - Options cancelled	'	$0.08	'
Weighted Average Exercise Price - Exercised	'	$0	'
Weighted Average Exercise Price - Ending Balance	'	$0.08	$0.05
Weighted Average Remaining Contractual Term-Balance	'	'9 years 1 month 6 days	'9 years
Outstanding Options Common Weighted Average Remaining Contractual Term - Employee	'	'9 years 6 months	'
Outstanding Options Common Weighted Average Remaining Contractual Term - Non-Employee	'	'9 years 6 months	'

STOCK_OPTION_PLANS_Details_1

STOCK OPTION PLANS (Details 1) (USD $)	0 Months Ended	9 Months Ended	12 Months Ended
	Mar. 07, 2014	Sep. 30, 2014	Dec. 31, 2013
		Stock Plan 2014 [Member]	Stock Plan 2014 [Member]
Outstanding Balance - Beginning	'	0	'
Common Stock Option Outstanding - Options granted Employees	'	5,400,000	'
Common Stock Option Outstanding - Options granted Non-Employee	'	0	'
Common Stock Option Outstanding - Options Cancelled	'	0	'
Common Stock Option Outstanding - Options Exercised	60,000,000	0	'
Outstanding Balance - Ending	'	5,400,000	0
Preferred options vested	'	84,791	'
Weighted Average Exercise Price - Beginning Balance	'	$0	'
Weighted Average Exercise Price - Options granted Employee	'	$0.09	'
Weighted Average Exercise Price - Options granted Non-Employee	'	$0	'
Weighted Average Exercise Price - Options cancelled	'	$0	'
Weighted Average Exercise Price - Exercised	'	$0	'
Weighted Average Exercise Price - Ending Balance	'	$0.09	$0
Weighted Average Remaining Contractual Term-Balance	'	'10 years	'0 years
Outstanding Options Common Weighted Average Remaining Contractual Term - Employee	'	'10 years	'
Outstanding Options Common Weighted Average Remaining Contractual Term - Non-Employee	'	'0 years	'

STOCK_OPTION_PLANS_Details_2

STOCK OPTION PLANS (Details 2) (2012 Preferred Stock Plan [Member], USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
2012 Preferred Stock Plan [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Outstanding Balance - Beginning	2,287,500	'
Preferred Stock Option Outstanding - Options granted Employees	200,000	'
Preferred Stock Option Outstanding - Options granted Non-Employee	0	'
Preferred Stock Option Outstanding - Preferred options cancelled	0	'
Outstanding Balance - Ending	2,487,500	2,287,500
Preferred options vested	1,818,099	'
Weighted Average Exercise Price - Beginning Balance	$0.47	'
Weighted Average Exercise Price - Options granted Employee	$2.21	'
Weighted Average Exercise Price - Options granted Non-Employee	$0	'
Weighted Average Exercise Price - Preferred options cancelled	$0	'
Weighted Average Exercise Price - Ending Balance	$0.61	$0.47
Outstanding Preferred Options Weighted Average Remaining Contractual Term - Balance	'8 years 1 month 6 days	'8 years 6 months
Outstanding Preferred Options Weighted Average Remaining Contractual Term - Options granted Employee	'9 years 3 months 18 days	'
Outstanding Preferred Options Weighted Average Remaining Contractual Term - Options granted Non-Employee	'0 years	'
Outstanding Preferred Options Weighted Average Remaining Contractual Term - Preferred options cancelled	'0 years	'

STOCK_OPTION_PLANS_Details_3

STOCK OPTION PLANS (Details 3) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	$439	$84	$914	$682
Research and Development Expense [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	124	64	311	366
General and Administrative Expense [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	$315	$20	$603	$316

STOCK_OPTION_PLANS_Details_4

STOCK OPTION PLANS (Details 4)	3 Months Ended			9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013		Sep. 30, 2014	Sep. 30, 2013
Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]	'	'		'	'
Weighted-average volatility	289.00%	0.00%	[1]	300.00%	108.00%
Weighted-average expected term	'5 years 7 months 6 days	'0 years	[1]	'5 years 5 months 8 days	'5 years
Expected dividends	0.00%	0.00%	[1]	0.00%	0.00%
Risk-free investment rate	1.89%	0.00%	[1]	1.90%	0.50%
[1]	There were no options granted in the three months ended September 30, 2013

STOCK_OPTION_PLANS_Details_Tex

STOCK OPTION PLANS (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	12,700,000	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$1,620	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'2 years 6 months	'
Stock-based compensation	914,000	682,000
Non Employee [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	3,301,323	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	2,301,323	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	1,000,000	'
Stock-based compensation	$93	'
Chief Financial Officer [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	8,000,000	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$0.08	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	'25 percent upon grant and 1/36 per month thereafter	'
Chief Financial Officer [Member] | Time Based Shares [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	4,000,000	'
Chief Financial Officer [Member] | Performance Shares [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,000,000	'
Chief Financial Officer [Member] | Market Based Shares [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,000,000	'
Stock Plan 2008 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	46,119,832	'
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	'10 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'4 years	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$0.08	'
Preferred Stock Plan 2012 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$1.61	'
Preferred Stock Plan 2012 [Member] | Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'3 years	'
Preferred Stock Plan 2012 [Member] | Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'2 years	'
Stock Plan 2014 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	'10 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'4 years	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$0.09	'
Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares in Deficit	153,380,168	'

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	3 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Nov. 03, 2014
		Subsequent Event [Member]
Subsequent Event [Line Items]	'	'
Common stock issued for purchase under stock purchase agreement	'	$885
Common stock issued as consideration for stock purchase agreement	$1,330	$12
Common stock issued for purchase under stock purchase agreement in shares	9,000,000	11,514,120
Common stock issued as consideration for stock purchase agreement in shares	232,785	154,855